Key Takeaways
- Integrated model gains traction: Sai converted a second large pharma relationship into a strategic, end-to-end engagement and started integrated discovery programs with two large pharma customers, validating the full-service CRO-CDMO thesis.
- Capacity build-out stays on track: Bidar's 220 KL expansion is ready for commercial batches, while the second 225 KL block slipped to Q3 FY28 as the company prioritized other customer capability builds.
- Biotech green shoots appear: Enquiry uptick from biotech customers, particularly for integrated engagements in new modalities like peptides, signals a potential funding-cycle revival.
- Second-half skew reaffirmed: Management expects a stronger H2, but declined to quantify the ramp.
- What to watch next quarter: Whether the two new integrated discovery programs convert to material revenue, the pace of commercial batch commencement at Bidar, and any further biotech enquiry conversion.
Strategic Integrated Engagements
- Model validation: The first end-to-end integrated collaboration with a top-tier market-cap pharma company commenced operations, and a second large pharma relationship was converted into a similar strategic engagement this quarter.
- Discovery integration: Integrated discovery programs were started with two large pharma customers; these programs are currently small but demonstrate the model's appeal.
- Pipeline ambition: Management is in discussions with a few more large pharma customers to extend the integrated strategic engagement model, aiming to build a robust, consistent, and predictable long-term pipeline.
- No revenue visibility offered: Management explicitly declined to provide revenue potential or wallet share for these collaborations, stating "We don't give any guidance in that count. We've never done and never will."
- Pace caveat: Contract negotiations move slowly and may not mature; management noted "it may or may not mature as well. There is a conversation. They might not mature."
Krishna Kanumuri: "I think the important thing here... to look at is the fact that we are the only company which has significant scale in all three dimensions, so discovery, development, and commercial."
Capacity Expansion & Capex
- Bidar ready: The expanded small molecule manufacturing capacity of around 220 KL at Bidar is now ready, with final quality trials underway ahead of commencing commercial batches; this capacity is expected to be revenue-accretive in the current year.
- Second block recalibrated: Commissioning of the additional 225 KL capacity is now expected by Q3 FY28, a delay from the earlier timeline, because other capability needed by a couple of large pharma customers was prioritized. Management does not expect this to affect FY28 revenue commitments.
- H1 capex incurred: ₹621 crores spent in H1 FY27 (₹358 crores in Q2); the company remains on track with the overall FY27 capex plan of ₹1,100–₹1,300 crores.
- Next greenfield: Design work on a new manufacturing site in Telangana has commenced; ground-breaking is expected in Q4 FY27 (January/February). The land parcel is larger than the current site in Bidar and can support capacity higher than what we have here, with multimodalities.
- Funding stance: Management is comfortable with current leverage and committed to not starving the business of capex; if needed, it will return to the market or take on debt. A three-to-four-year capex guidance was declined.
Siva Chittor: "This business is a service business unless you put up capacity and unless you're available and be ready, customers will move up their products from a clinical phase to some other supplier in commercial. What you will get to hear is potentials and possibilities."
Pipeline & Portfolio Progression
- Late-phase pipeline: Phase III and pre-registration programs stood at 14 as of June; one molecule moved out and one came in, leaving the count flat. The 11 figure in the Q1 presentation was as of March 31, 2026; three molecules were added subsequently.
- Commercial molecules: One molecule moved from late-phase to commercial during the quarter, and one lateral entry was added, bringing total commercial molecules to 34. The discovery-to-market count remains at 5.
- CRO utilization: The new CRO block was at 85–90% utilization as mentioned in the previous quarter; the company is already adding more CRO capacity.
- Headcount growth: Headcount increased to around 4,400 at the end of September, reflecting people-related growth to support the business.
New Modalities
- Peptide progress: The first peptide development lab was commissioned during the quarter; additional peptide development labs are under construction and expected in the next few months.
- Peptide plant timeline: Design work for the new peptide plant in Telangana is ongoing; ground-breaking is expected in Q4 (January/February) once the master plan is complete.
- ADC and bioconjugation: Discovery sites are active; Class 6 containment labs for cross-development are coming online soon; CMC labs are almost online this year.
- Gradual migration: Management expects a gradual shift to newer modalities over the next two to three years as customers get comfortable with delivery and relationships, not a sudden shift overnight. India will be a player in most modalities because of small-molecule backbones.
- Technology evolution: Technology in peptides and oligonucleotides is changing dramatically; the company is focused on ensuring its technology is ready and evolving with the direction of the field.
Demand Environment & End-Market Dynamics
- Pharma-led growth: Over the last 10–15 months, growth in large pharma has been a big factor driving overall growth; the CRO pharma split reached 40% as of the end of 2026, up from minimal presence a few years ago.
- Biotech revival signs: An uptick in enquiries from biotech customers was witnessed, with many enquiries for integrated engagements in new modalities, specifically peptides. Biotech funding is in a mid-phase cycle of selling late-stage assets; new company formation is expected to start once that cycle completes, with early green shoots from increased IPOs and acquisitions.
- India's strategic shift: Management observed that large pharma companies are now thinking about how to become strategic with one or two companies in India, moving beyond India's historical role as a tactical supplier for specific projects.
- Raw material pressure: A modest increase in raw material costs, particularly certain solvents and chemicals, arose from the ongoing Middle East situation; supply-chain teams ensured continuity, and the company is working with customers to recover incremental costs.
Krishna Kanumuri: "India was a more of a tactical supplier where they would come for some projects. But now almost every large pharma is thinking about how do you become strategic with a few, maybe one or two companies in India."
AI & Discovery Services
- Net positive for India: Management sees AI as a net positive for India's CDMO industry; better-quality tools for process optimization and process development make the company more competitive.
- No budget compression: Pharma counterparts have told management that AI's outcome will probably be more molecules rather than reducing budgets, depending on success. More molecules in the clinic help the development side.
- Discovery services resilient: Management does not see a significant AI impact on discovery services because, regardless of design, molecules must still be made and tested.
Krishna Kanumuri: "I think AI impact on discovery services will not be significant, because end of the day, I think no matter what the design is, you have to continue to make the molecules and test the molecules."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Bidar capacity revenue contribution | Expanded 220 KL capacity to be revenue-accretive | FY27 |
| Second 225 KL block commissioning | Now expected early Q3 FY28; no impact on FY28 revenue commitments | Early Q3 FY28 |
| Telangana greenfield ground-breaking | Design work commenced; ground-breaking expected | Q4 FY27 (Jan/Feb) |
| FY27 capex plan | ₹1,100–₹1,300 crores; ₹621 crores incurred in H1 | FY27 |
| Second-half performance | Stronger H2 expected; historical 40:60 H1/H2 split | H2 FY27 |
| Capex funding | Will not starve business of capex; will use leverage, debt, or market if needed | Ongoing |
| New modalities migration | Gradual shift over two to three years as customers gain comfort | 2–3 years |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue growth | 23% YoY |
| CDMO business growth | 20% YoY |
| CRO business growth | 28% YoY |
| H1 FY27 revenue growth | 17% YoY |
| H1 FY27 revenue split | CRO 38%, CDMO 62% |
| EBITDA margin | 28% of revenue, in line with YoY margin trajectory |
| H1 FY27 EBITDA margin | 28% |
| Q2 FY27 capex incurred | ₹358 crores |
| H1 FY27 capex incurred | approximately ₹621 crores |
| FY27 capex plan | ₹1,100 crores–₹1,300 crores |
| Headcount | around 4,400 at end of September |
| Active NCE molecules | 34, up from 33 last quarter; one molecule moved from late phase to commercial |
| Late-phase pipeline | 14 programs, net addition from 11 to 14 from Q1 to Q3 |
| Commercial molecules | 34 programs |
| Large pharma clients | 19 out of 25 |
| Largest customer concentration | around 12% of revenue at end of last year |
| CDMO capacity utilization | 67% in Q2 |
| Expanded manufacturing capacity at Bidar | around 220 KL, ready; final quality trials underway |
| Additional capacity commissioning | 225 KL now expected by early Q3 FY28, moved from Q4 FY27 |
| CRO pharma split | 40% as of end of 2026 |
| Molecules taken from discovery to market | 5 |
| Returning customer revenue | over 90% of revenues |
| Cash reserves | close to ₹100 crores |
| Internal accrual | ₹400 crores–₹500 crores |
| Staff turnover | about a fifth each year |